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Abstract
Angiogenesis is an important process in chronic inflammatory
diseases. We observed that sera from patients with systemic
vasculitis stimulated angiogenesis in an in vitro model using
human umbilical vein endothelial cells cultured on a basement
membrane (Matrigel) substrate. After 40% ammonium sulfate
precipitation, angiogenic activity remained in the low molecular
weight fraction and could be inactivated by heat. SDS-page of
serum FPLC fractions exhibiting maximal angiogenic activity
demonstrated two prominent species of 45 and 16-20 kD in
patients' sera. These bands were much less apparent in sera
obtained from control subjects. Amino-terminal sequencing of
the 45-kD protein demonstrated that it was haptoglobin. Puri-
fied haptoglobin stimulated angiogenesis in a dose-dependent
manner. The angiogenic activity of vasculitis patients' sera was
partially inhibited by an antihaptoglobin antibody. Further-
more, serum haptoglobin levels in vasculitis patients correlated
both with disease and angiogenic activity. Haptoglobin angio-
genic activity was confirmed in two in vivo models using an
implanted disc and a subcutaneous injection of basement mem-
brane. Stimulation ofangiogenesis is a newly recognized biologi-
cal function of haptoglobin. The increased levels of haptoglobin
found in chronic inflammatory conditions may play an impor-
tant role in tissue repair. In systemic vasculitis, haptoglobin
might also compensate for ischemia by promoting development
of collateral vessels. (J. Clin. Invest. 1993. 91:977-985.) Key
words: vasculitis * inflammatory diseases * angiogenesis* base-
ment membrane * endothelial cell
Introduction
Angiogenesis plays an important role in a variety ofphysiologi-
cal and pathological conditions, such as embryonic develop-
ment, tumor growth, wound healing, and chronic inflamma-
tory diseases ( 1 ). The formation ofnew blood vessels involves
dissolution of the underlying basement membrane, followed
by cell migration, alignment, proliferation, differentiation into
tubular structures, and finally reestablishment of a new base-
ment membrane (2, 3). The basement membrane is an impor-
tant biological mediator of this process and this has been ex-
ploited in both in vitro and in vivo assays to assess the angio-
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genic activity ofvarious factors (4-7). Endothelial cells grow as
a monolayer on plastic, but when plated on a reconstituted
basement membrane (Matrigel), they cease to proliferate and
differentiate into a complete network of capillary-like struc-
tures within 12-18 h (8, 9). To undergo differentiation, endo-
thelial cells require unidentified soluble factors present in
serum (1O). The Matrigel in vitro model has significant advan-
tages compared with other methods in which only a small per-
centage ofthe cells differentiate during a period oftime ranging
from one to several weeks and in which quantitation is difficult
(1 1, 12). Matrigel can also be injected subcutaneously in mice
and used as a vehicle to assess angiogenic activity of different
compounds (13, 14). Subcutaneous injection of Matrigel
alone is not associated with focal angiogenesis. However, if
fibroblast growth factor-heparin is mixed with Matrigel before
injection, ingrowth of vessels is observed within days. The Ma-
trigel plugs can be easily removed by dissection, fixed, stained
and the newly formed vessels can be quantitated ( 13, 14). To
date, the factors tested in vitro and in vivo Matrigel assays show
similar activities to those observed in the chick chorioallantoic
membrane (9, 13-15).
Systemic vasculitis includes a heterogeneous group of dis-
orders characterized by inflammation of blood vessels. Exam-
ples of major systemic vasculitic syndromes are polyarteritis
nodosa, Churg-Strauss syndrome, Wegener's granulomatosis
(WG),' giant-cell (temporal) arteritis, and Takayasu's disease
(16, 17). The inflammatory process often leads to the occlu-
sion or stenosis of the vascular lumen either by thrombus or by
both myointimal proliferation and fibrosis, resulting in isch-
emia or infarction. Histopathologic studies of affected tissues
often reveal new reparative vessels (reference 18; Cid, M. C., et
al., unpublished observations). The factor(s) that trigger this
angiogenic response are not known. We have tested sera from
vasculitis patients at various stages of the disease and have
found potent angiogenic activity using both in vitro and in vivo
angiogenesis models. Haptoglobin, which is not known to have
angiogenic properties, was identified as one of the angiogenic
substances present in serum.
Methods
Patient material. Serum samples were obtained from 38 individuals
with systemic vasculitis and from 19 healthy blood donors. 28 patients
had WG, 6 had biopsy-proven giant-cell (temporal) arteritis, and 4 had
Takayasu's disease. 11 WG patients had limited disease, clinically re-
stricted to upper and/or lower airways and 17 had generalized WG
1. Abbreviations used in this paper: FPLC, fast performance liquid
chromatography; Hpr, haptoglobin-related protein; HUVEC, human
umbilical vein endothelial cells; WG, Wegener's granulomatosis.
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including kidney involvement. When serum samples were obtained, 16
WG patients had active disease, 5 patients had inactive disease with
immunosuppressive therapy, and 9 patients were in complete remis-
sion without treatment. Two patients were tested twice during active
and inactive disease. All temporal and Takayasu's arteritis patients had
evidence of active disease.
Endothelial cell culture. Human umbilical vein endothelial cells
(HUVEC) from fresh placental cords were isolated by previously de-
scribed methods ( 19) and grown until confluence at 370C in 5% Co2.
The growth medium consisted of Medium 199 (Gibco Laboratories,
Grand Island, NY) supplemented with 20% bovine calf serum (Hy-
clone Laboratories Inc., Logan, UT), 200 gg/ml endothelial cell
growth supplement (Collaborative Research, Bedford, MA), 100 U/
ml penicillin-streptomycin, 50 qg/ml gentamicin, 2 mM glutamine
(Gibco Laboratories), and 50 U/ml sodium heparin (Fisher Scientific,
Fair Lawn, NJ). Cells used for experiments were from passage 4 to 8.
In vitro angiogenesis model. The reconstituted basement mem-
brane, Matrigel, was extracted from the murine Engelbreth-Holm-
Swarm tumor as previously described (20), sterilized with chloroform,
and dialyzed against Medium 199. 24-well plates (Costar Corp., Cam-
bridge, MA) were coated with 300 1d of Matrigel per well, which was
allowed to polymerize at 370C for 30 min. HUVEC (30,000 per well)
suspended in Medium 199 were plated on Matrigel and either patients'
or controls' sera at a concentration of5% in a final volume of 1 ml were
added. These conditions oflow serum and low cell number are subopti-
mal for endothelial cell differentiation in this assay (9, 10) and were
selected so as to detect factors that promote tube formation. After an
overnight incubation at 370C in 5% CO2, the capillary-like structures
(tubes) were fixed and stained with Diff-Quik (Baxter Healthcare Cor-
poration, McGaw Park, IL) and the total tube area per well in duplicate
wells was measured at I Ox magnification with a computerized digital
analyzer (Optomax Inc., Hollis, NH). In subsequent experiments,
commercial haptoglobin purified from pooled human plasma (pheno-
types 1.1, 2.1, and 2.2; Sigma Chemical Co., St. Louis, MO) was tested
in triplicate in the same system at different concentrations ranging
from 10 to 100 ,gg/ml. In addition, the purified IgG fraction ofeither a
rabbit anti-human haptoglobin antiserum (Sigma Chemical Com-
pany) or nonimmune rabbit serum (Zymed Laboratories Inc., San
Francisco, CA) was added to the culture medium at a 1:20 dilution and
tube formation was assessed as described above. Each assay was re-
peated three times with comparable results.
Purification ofthe angiogenicfactor(s)from WG serum. Samples of
medium containing 14% serum from either patients or controls were
precipitated with 40% ammonium sulfate. The supernate and the pre-
cipitate were dialyzed against M 199 and angiogenic activity was tested
at 1:2 dilution in the in vitro Matrigel assay.
1 ml of the 40% ammonium sulfate supernate was applied to an
FPLC column (Superose-6; Pharmacia LKB Biotechnology Inc.,
Piscataway, NJ) and eluted with DPBS- Gibco Laboratories). The an-
giogenic activity of the fractions obtained was tested in the in vitro
Matrigel assay in the presence of 2% BCS. The fractions with highest
activity were dialyzed against distilled H20, lyophilized, and electro-
phoresed in 10% SDS-PAGE under reducing conditions as previously
described (21 ).
Amino acid sequencing. Active fractions from the FPLC column
from different patients' serum samples were electrophoresed in SDS-
PAGE, transferred onto a nylon sheet (Immobilon; Millipore Corpora-
tion, Bedford, MA), fixed with 100% methanol, and stained with
freshly prepared 0.1% Coomassie brilliant blue R-250 (Sigma Chemi-
cal Co.) in 50% methanol/ 10% acetic acid. The amino-terminal se-
quencing of the 45 kD band that appeared in the active fractions was
performed directly from Immobilon paper by Matt Williamson (Uni-
versity of California, San Diego).
Haptoglobin serum levels determination. Haptoglobin serum con-
centration was measured by nephelometry (American Medical Labora-
tories, Fairfax, VA) in 25 patients with WG (10 with active disease, 6
Figure 1. Endothelial cell differentiation on Matrigel. At low cell density and at low serum concentration, sera from systemic vasculitis patients
strongly stimulate endothelial cell differentiation into capillary-like structures. (A) Only fragments of unconnected tubes appear with control
serum. (B) Complete network induced by WG serum. Tubes are fixed and stained with Diff-Quik. X50.
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who were asymptomatic and receiving immunosuppressive therapy,
and 9 who were untreated and in remission) and 10 healthy controls.
In vivo Matrigel assays. Matrigel (liquid at 40C) was mixed with
various concentrations of commercially obtained (Sigma Chemical
Co.) human haptoglobin 1.1 or haptoglobin 2.2 at a final concentration
of0.5, 1,and 2 mg/ml. In some experiments, haptoglobin was first heat
inactivated at 1000C for 15 min. Matrigel alone or mixed with test
haptoglobin (0.5 ml total volume) was injected subcutaneously into
immunodeficient mice (NIH beige nude XID) in duplicate ( 13, 14).
After 10 d, the animals were killed, and the Matrigel plugs were re-
moved together with the abstract epidermis and dermis, fixed in 3.7%
formaldehyde, and embedded in paraffin. Histological sections were
stained with Masson's trichrome. The vessel area in histological sec-
tions of the Matrigel plug was measured using a computerized digital
analyzer (Optomax Inc.). A total of 20 fields (10OX magnification)
were evaluated for each specimen. The experiment was repeated three
times.
In vivo disc angiogenesis model. This assay was performed essen-
tially as described by Fajardo et al (22) with minor modifications (23).
The central core of a polyvinyl sponge disc was removed and permitted
to absorb 40 ug of either haptoglobin purified from pooled human
plasma containing all three isotypes ( 1.1, 2.1, 2.2) (Calbiochem Corp.,
San Diego, CA), purified haptoglobin 1.1, purified haptoglobin 2.2
(Sigma Chemical Co.) or PBS as a negative control. The loaded sponge
core was then coated with ethylene vinyl copolymer (Elvax) to achieve
a slow release preparation. The core was reinserted into the sponge disc
and the whole disc was covered on its broad surfaces by imperme-
ablized filter paper. Assembled sponges were then inserted subcutane-
ously into the flanks of adult (athymic) mice and recovered after 14 d
in vivo.
Discs were embedded in paraffin, sectioned tangentially (20 Mm),
and stained with hematoxylin/eosin to permit visualization of the area
of the disc penetrated by migrating cells. Discs were analyzed using an
image analysis system to determine the percent of disc area penetrated
by cells.
Results
Angiogenic activity of vasculitis patients' sera. At a low (5%)
control serum concentration and low cell density, the forma-
tion of capillary-like tubes by HUVEC plated on Matrigel was
marginal and many incomplete tubes were formed. In contrast,
under the same conditions, sera from patients with systemic
vasculitis stimulated tube formation on Matrigel (Fig. 1 ). Sera
from WG patients had greater angiogenic activity than those
from patients with either Takayasu's disease or giant-cell (tem-
poral) arteritis (Fig. 2 A). Hence, serum samples from WG
patients were used in all the subsequent experiments. Serum
angiogenesis assays performed during different stages ofWG
disease activity demonstrated that angiogenic activity persisted
longer than clinical signs ofactive disease, although the angio-
genic activity did decline when patients achieved complete re-
mission (Fig. 2 B).
Purification ofthe angiogenicfactor(s)from WG sera. Ini-
tial characterization of the angiogenic factor(s) present in WG
serum demonstrated that the angiogenic activity remained in
the serum supernate after 40% ammonium sulfate precipita-
tion. The capillary-like network obtained with the serum su-
pernate was complete and indistinguishable from that obtained
with whole serum. The angiogenic activity was absent from the
40% ammonium sulfate pellet and was completely abolished
by heating the serum supernate. These data suggested that the
activity resided in the low molecular weight protein fraction.
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Subjects
Figure 2. (A) Angiogenic activity in serum samples from different
vasculitis patients. Patients include eight with Wegener's granuloma-
tosis (WG), four with Takayasu's disease (TD), six with giant-cell
(temporal) arteritis (GCA), and eight controls (c). Each dot repre-
sents the average ofthe tube area per well in duplicate for each sam-
ple. Tube area is expressed in mm2. (B) Angiogenic activity ofWG
patients' sera at different stages of the disease. This experiment in-
cludes serum samples from 10 patients with active disease, 4 patients
receiving therapy, 4 untreated patients in remission, and 6 controls.
Bars represent the mean + SE of the values obtained as described
above in each group of individuals.
graphed on Superose 6 by FPLC to purify the factor responsible
for the increase in angiogenic activity observed in WG sera. A
consistent difference in optical density profiles was observed in
nine patients with WG and three normal controls. The WG
sera had a larger peak in fractions 35-40 (Fig. 3). When all the
fractions were tested in the in vitro Matrigel tube assay, these
same fractions were found to contain the maximal angiogenic
activity.



























Haptoglobin levels were elevated during active disease in
WG patients, decreased during treatment and improvement,
Control 4 _and were similar to controls during untreated remission (Fig. 5
A). No differences in haptoglobin concentration were found
among WG patients with different patterns of organ involve-
ment. The angiogenic activity tested simultaneously in the in
vitro Matrigel assay in 14 WG patients (6 active, 3 treated, and
5 in remission) and 5 controls correlated with the correspond-
ing haptoglobin levels (Fig. 5 B).
Haptoglobin stimulation of endothelial cell differentiation
in vitro. Purified haptoglobin stimulated tube formation in a
20 30 40 50 60 70 80 dose-dependent manner (Fig. 6). Tube-forming activity re-
quired the baseline presence of 2% bovine calf serum, indicat-
Fraction Number ing that haptoglobin is necessary but not sufficient to stimulate
ure 3. Optical density profile ofWG and control serum supernates tube formation. Of the three major haptoglobin phenotypes,
:r 40% ammonium sulfate precipitation in the first 100 FPLC haptoglobin 2.2 was most active, the heterozygous 2.1 had in-
-tions. WG fractions contained a larger peak in 35-40 fractions, termediate activity, and haptoglobin 1.1 had the least activity
ich manifested the highest angiogenic activity. (data not shown).
The angiogenic activity of 7% WG serum was partially in-
hibited by the IgG fraction of a rabbit antihuman haptoglobin
antiserum. Tubes remained well constituted and the inhibitory
SDS-PAGE ofthe active FPLC fractions ofWG sera under effect was mainly a decrease in the branching points and in the
lucing conditions showed two bands of45 and 16 kD, respec- number of interconnected tubes (Fig. 7). A similar inhibitory
dly. These same bands could be detected in fractions from effect of the antihaptoglobin antibody was observed on the
control sera but their levels were greatly reduced (Fig. 4). tube-forming activity promoted by complete medium which
is difference was consistent in nine individuals (six WG and contains 20% bovine calf serum, or on the lesser activity pres-
ee controls) tested. ent in 7% normal human control sera (data not shown). The
The sequence of the 18 amino-terminal amino acids of the addition of nonimmune rabbit IgG did not influence tube for-
kD protein was found to be identical to the beta chain of mation (Fig. 7). These data suggest that one of the active an-
man haptoglobins (24-27). giogenic compounds present in serum is haptoglobin.
1 2 3 4 5 6
WG FRACTIONS
7 8 9 10 11 12 13
CONTROL FRACTIONS
Figure 4. Coomassie blue-stained 10% SDS-polyacrylamide gel of the FPLC fractions with maximal angiogenic activity shows two bands of - 45
and 16 kD elevated in the fractions from the WG patient (lanes 1-6) and reduced in the fractions of a normal blood donor (lanes 7-13).
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Figure 5. (A) Hap
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Figure 6. Dose response of the angiogenic activity of purified hapto-
globin 2.2 on Matrigel in vitro. Bars represent the mean±SE of the
total tube area in triplicate wells.
/ were observed (Fig. 8). The angiogenic effect was apparent at a
concentration of 2 mg/ml, which is within the high physiologi-
cal range. In this in vivo model, haptoglobin 2.2 was much
0 more active than haptoglobin 1.1, as was noted in the in vitro
* assay described above.
° To exclude any additional effect of Matrigel beside provid-
ing extracellular matrix compounds and a physical system to
D deliver factors to be tested, we confirmed our experiments in
another in vivo angiogenesis model: the disc angiogenesis sys-
______. _____, _____, _____, _____, tem. In this model, haptoglobin 1.1 induced vessel penetration
2 3 4 5 6 , in 19.8±4.4% (mean±SE) of the disc area; haptoglobin from
pooled plasma, 22.9±2.2%; and haptoglobin 2.2, 27+2.9%. In
Haptoglobin level (mg/ml) PBS-treated discs, blood vessels invaded only 15.5±2.5% ofthe
disc surface. In the disc angiogenesis model, the angiogenic
xtoglobin levels in WG patients at different stages of 40'
represent the mean±SE in 10 active patients, 6 activity induced by 40,gg of haptoglobin 2.2 was equivalent to
ients receiving immunosuppressive treatment, 9 in that achieved with 2-4 ng of basic fibroblast growth factor.
remission and not requiring therapy, and 10 controls. (B) Significant
correlation between haptoglobin levels and the corresponding angio-
genic activity of samples from 14 WG patients (o) and 5 controls
(a ) (r = 0.57, P = 0.01 1). WG population includes six patients with
active disease, three treated and asymptomatic, and five in remission
and untreated.
In vivo angiogenesis models. In vivo, haptoglobin stimu-
lated vascularization of the subcutaneously injected Matrigel
plug in a dose-dependent manner and its activity was abro-
gated by prior heating (Figs. 8 and 9). In plugs containing
Matrigel alone, only a few cells invaded the plug at the periph-
ery. Haptoglobin-containing plugs differed from those contain-
ing Matrigel alone, not only in the density but in the depth that
endothelial cells invaded the matrix. In addition, when hapto-
globin was present, well- constituted and functional vessels
Discussion
The present study demonstrates that sera from systemic vascu-
litis patients manifest angiogenic properties. The isolation and
purification of serum angiogenic fractions led to the identifica-
tion of haptoglobin as one of the angiogenic factors. Antihap-
toglobin antibodies partially inhibited the angiogenic activity
promoted by regular endothelial growth medium, which con-
tains 20% bovine calf serum, suggesting that haptoglobin may
be one of the substances normally present in serum that is
required for endothelial cell differentiation. Purified haptoglo-
bin required the presence of 2% serum to show an angiogenic
effect, indicating that it is necessary but not sufficient for angio-
genic stimulation in vitro with HUVEC on Matrigel. In vivo,
haptoglobin was angiogenic in both the subcutaneous disc and
Matrigel implant model systems.





















Figure 7. The angiogenic activity ofWG serum is partially inhibited by an antihaptoglobin antibody. (A) Tube formation induced by 7% WG
serum. (B) Tube formation promoted by 7% WG serum after the addition of an antihaptoglobin antibody. (C) Tube formation stimulated by
WG serum and a nonimmune rabbit IgG. Hoffman modulation contrast of nonstained tubes. x30.
Haptoglobin is a plasma alpha2-glycoprotein consisting of
an alpha and a beta polypeptide chain of 16-20 kD and 45 kD,
respectively, linked by disulfide bonds that originate after pro-
teolytic cleavage from a single precursor (24-27). Human hap-
toglobin has three major allelic forms, haptoglobin 1.1, hapto-
globin 2.2, and the heterozygous 2.1, which are defined by dif-
ferences in the alpha chain. The human haptoglobin gene has
been cloned and the entire genomic DNA sequenced (28). A
haptoglobin-related sequence (Hpr) is located 2.2 kb down-
stream of the haptoglobin gene (28). It is unclear if Hpr is
expressed and the function of its theoretical product is still
unknown. The haptoglobin gene is expressed in hepatocytes
and in several hepatoma cell lines where it is upregulated by
several cytokines, particularly IL-6 (29-33).
The best known biological function of haptoglobin is as a
carrier for free hemoglobin. The high affinity haptoglobin-he-
moglobin complex is taken up by hepatocytes and catabolized
(34, 35). The adaptative value of this process appears to be
prevention of both iron loss and kidney damage during hemo-
lysis. In addition, plasma levels ofhaptoglobin increase in both
acute and chronic inflammatory diseases (36, 37). In these
situations, it has been considered to be part of a nonspecific
response triggered by systemically released cytokines that cause
altered hepatic synthesis of major plasma proteins (30-32).
The significance ofincreased levels ofhaptoglobin in these situ-
ations has not been clearly elucidated.
Our studies demonstrate angiogenic activity as a newly rec-
ognized function ofhaptoglobin. Persistent elevations ofserum
haptoglobin in the setting of inflammation and ischemia may
play a role in compensatory angiogenesis. Although angiogene-
sis is a complex process affected by a variety of factors, we
found a significant correlation between serum haptoglobin lev-
els in patients with WG and serum angiogenic activity. There-
fore, the angiogenic activity of haptoglobin may be important
in chronic inflammatory diseases where it can promote tissue
repair. In systemic vasculitis, it may compensate for ischemia
by stimulating the development of collateral vessels. The per-
sistence ofserum angiogenic activity and elevated serum hapto-
globin levels beyond the period of clinically active disease in
WG further suggests an important reparative role for this pro-
tein.
Elevated serum concentrations ofhaptoglobin also occur in
the setting of pregnancy (38), myocardial infarction (39), and
cancer (39, 40). In a variety ofmalignancies, haptoglobin con-
centration correlates with disease progression (40-43). Angio-
genesis is an important phenomenon in all of these conditions
(44-46). In myocardial infarction, the haptoglobin 2.2 pheno-
type is associated with a worse prognosis defined by a greater
incidence of left ventricular failure and shorter survival (47,
48). It has been suggested that the worse prognosis of myocar-
dial infarction in patients carrying the haptoglobin 2.2 pheno-
type could be explained by a deleterious effect of haptoglobin
2.2 itself. Conversely, haptoglobin-stimulated microangiogen-
esis may have allowed patients with atherosclerosis to be spared
myocardial infarction until more advanced stages of coronary
disease (47). Our observation that haptoglobin 2.2 is more
angiogenic than other phenotypes supports the latter hypothe-
sis. If the angiogenic activity of haptoglobin is relevant in vivo
in these conditions, other unknown factors must regulate and
target its effects where required.
The enhanced angiogenic activity present in vasculitis sera
compared with controls may be due to quantitative differences
in haptoglobin concentration or to the presence of a different
haptoglobin with higher angiogenic activity. Immunochemi-
cally and functionally different haptoglobins have been de-
scribed in other pathological conditions. For example, hapto-
globin purified from malignant effusions is structurally similar
to fetal haptoglobin and has immunosuppressive properties
that are more potent than that of adult haptoglobin (42-44).
Cancer or fetal haptoglobins and normal adult haptoglobin
differ primarily because of postranslational modifications that
include variations in glycosylation (42, 43). Abnormally gly-
cosylated forms of haptoglobin have also been described in
chronic inflammatory diseases such as rheumatoid arthritis
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Figure 9. Dose response of purified haptoglobin 2.2 in the in vivo
Matrigel angiogenesis assay. Bars represent the mean± 1 SE of the
vessel area in 20 fields of each specimen. Heat inactivation (HI)
strongly reduces haptoglobin activity.
(49). Immunohistochemical detection of haptoglobin with
epitopes corresponding to the predicted sequence of the Hpr
product has been recently described in advanced prostatic tu-
mors (50) and in breast cancer, where its presence in initial
stages correlates with the occurrence of early metastasis (51 ).
In the present study, we did not determine whether the hapto-
globin present in patients' sera has structural differences that
could result in an increase in its angiogenic activity.
In summary, our studies demonstrate that haptoglobin
stimulates angiogenesis in both in vitro and in vivo models.
Haptoglobin elevation in chronic inflammatory and/or isch-
emic conditions may be important for tissue repair and in pro-
moting growth of collateral vessels.
Acknowledgments
M. C. Cid was supported by a grant from Fondo de Investigaciones
Sanitarias de la Seguridad Social (FISSS 91/ 53 10) and by the Fogarty
visiting program.
References
1. Folkman, J., and M. Klagsbrun. 1987. Angiogenic factors. Science (Wash.
DC). 235:442447.
2. Furcht, L. T. 1986. Critical factors controlling angiogenesis: cell products,
cell matrix, and growth factors. Lab. Invest. 55:505-509.
3. Liotta, L. A., P. S. Steeg, and W. G. Stetler-Stevenson. 1991. Cancer metas-
tasis and angiogenesis: an imbalance of positive and negative regulation. Cell.
64:327-336.
4. Madri, J. A., S. K. Williams, T. Wyatt, and C. Mezzio. 1983. Capillary
endothelial cell cultures: phenotype modulation by matrix components. J. Cell.
Biol. 97:153-166.
5. Ingber, D. E., and J. Folkman. 1989. How does extracellular matrix control
capillary morphogenesis? Cell. 58:803-805.
6. Ingber, D. E., and J. Folkman. 1989. Mechanochemical switching between
growth and differentiation during fibroblast growth factor-stimulated angiogene-
sis in vitro: role of extracellular matrix. J. Cell. Biol. 109:317-330.
7. Form, D. M., B. M. Pratt, and J. A. Madri. 1986. Endothelial cell prolifera-
tion during angiogenesis. In vitro modulation by basement membrane compo-
nents. Lab. Invest. 55:521-530.
8. Kubota, Y., H. K. Kleinman, G. R. Martin, and T. J. Lawley. 1988. Role of
laminin and basement membrane in the morphological differentiation ofhuman
endothelial cells into capillary-like structures. J. Cell. Biol. 107:1589-1598.
9. Grant, D. S., K. I. Tashiro, B. Segui-Real, Y. Yamada, G. R. Martin, and
H. K. Kleinman. 1989. Two different laminin domains mediate the differentia-
tion of human endothelial cells into capillary-like structures in vitro. Cell.
58:933-943.
10. Kinsella, J. L., D. S. Grant, B. S. Weeks, and H. K. Kleinman. 1992.
Protein kinase C regulates endothelial cell tube formation on basement mem-
brane Matrigel. Exp. Cell. Res. 199:56-62.
11. Montesano, R., L. Orci, and P. Vassali. 1983. In vitro rapid organization
of endothelial cells into capillary-like networks is promoted by collagen matrices.
J. Cell. Biol. 97:1648-1652.
12. Madri, J. A., and B. M. Pratt. 1986. Endothelial cell-matrix interactions:
in vitro models of angiogenesis. J. Histochem. Cytochem. 34:85-91.
13. Passaniti, A., R. M. Taylor, W. R. Gage, R. Pilli, Y. Guo, P. V. Long, J. A.
Haney, R. R. Pauley, D. S. Grant, and G. R. Martin. 1992. A new quantitative
method for assessing angiogenesis and anti-angiogenic agents using reconstituted
basement membrane, heparin and FGF. Lab. Invest. 67:519-528.
14. Kibbey, M. C., D. S. Grant, R. Auerbach, and H. K. Kleinman. 1992. The
SIKVAV site of laminin promotes angiogenesis and tumor growth in an in vivo
Matrigel model. J. Natl. Cancer Inst. 84:1633-1638.
15. Sakamoto, N., M. Iwahana, N. G. Tanaka, and Y. Osada. 1991. Inhibition
ofangiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-
NH2. Cancer Res. 51:903-906.
16. Fauci, A. S., B. F. Haynes, and P. Katz. 1978. The spectrum of vasculitis.
Clinical, pathologic, immunologic and therapeutic considerations. Ann. Intern.
Med. 89:660-676.
17. Cupps, T. R., and A. S. Fauci. 1981. The Vasculitides. W. B. Saunders,
Philadelphia.
18. Olsson, A., P. Elling, and H. Elling. 1990. Serological and immunohisto-
chemical determination of von Willebrand factor antigen in serum and biopsy
specimens from patients with arteritis temporalis and polymyalgia rheumatica.
Clin. Exp. Rheum. 8:55-58.
19. Jaffe, E. A., R. L. Nachman, C. G. Becker, and C. R. Minick. 1973.
Culture of human endothelial cells derived from umbilical veins. Identification
by morphological and immunological criteria. J. Clin. Invest. 52:2745-2756.
20. Kleinman, H. K., M. L. McGarvey, J. R. Hassell, V. L. Star, F. B. Cannon,
G. W. Laurie, and G. R. Martin. 1986. Basement membrane complexes with
biological activities. Biochemistry. 25:312-318.
21. Laemmli, U. K. 1970. Cleavage ofstructural proteins during the assembly
of the head of bacteriophage T4. Nature (Lond.). 227:680-685.
22. Fajardo, L. F., J. Kowalski, H. H. Kwan, S. D. Prionas, and A. C. Allison.
1988. The disc angiogenesis system. Lab. Invest. 58:718-724.
23. Polakowski, I. J., K. Lewis, and R. Auerbach. 1992. A protein RNase
inhibitor (RNasin) expresses anti-angiogenic properties in mice. In Angiogenesis,
Key Principles, Science, Technology, Medicine. R. Steiner, P. B. Weisz, and R.
Langer, editors. Birkhauser Verlag, Basel. 432436.
25. Raugei, G., G. Bensi, V. Romano, C. Santoro, F. Constanzo, and R.
Cortese. 1983. Sequence of human haptoglobin cDNA: evidence that the alpha
and beta subunits are coded by the same mRNA. Nucleic Acids Res. 11:581 I-
5819.
26. Yang, F., J. L. Brune, W. D. Baldwin, D. R. Barnett, and B. H. Bowman.
1983. Identification and characterization of human haptoglobin cDNA. Proc.
Natl. Acad. Sci. USA. 80:5875-5879.
27. vander Straten, A., A. Herzog, P. Jacobs, T. Cabezon, and A. Bollen. 1983.
Molecular cloning of human haptoglobin cDNA: evidence for a single mRNA
coding for alpha2 and beta chains. EMBO (Eur. Mol. Biol. Organ.) J. 2:1003-
1007.
28. Maeda, N. 1985. Nucleotide sequence of the haptoglobin and haptoglo-
bin-related gene pair. The haptoglobin-related gene contains a retrovirus-like
element. J. Biol. Chem. 260:6698-6709.
29. Milland, J., A. Tsykin, T. Thomas, A. R. Aldred, T. Cole, and G.
Schreiber. 1990. Gene expression in regenerating and acute-phase rat liver. Am. J.
Physiol. 259:G340-G347.
30. Iwasa, F., R. A. Galbraith, and S. Sassa. 1988. Effects ofdimethyl sulphox-
ide on the synthesis of plasma proteins in the human hepatoma HepG2. Induc-
tion of an acute-phase-like reaction. Biochem. J. 253:927-930.
984 Cid, Grant, Hoffman, Auerbach, Fauci, and Kleinman
31. Darlington, G. J., D. R. Wilson, and L. B. Lachman. 1986. Monocyte-
conditioned medium, interleukin-1, and tumor necrosis factor stimulate the
acute phase response in human hepatoma cells in vitro. J. Cell. Biol. 103:787-
793.
32. Castell, J. V., M. J. Gomez-Lechon, M. David, T. Andus, T. Geiger, R.
Trullenque, R. Fabra, and P. C. Heinrich. 1989. Interleukin-6 is the major regula-
tor ofacute phase protein synthesis in adult human hepatocytes. FEBS (Fed. Eur.
Biochem. Soc.) Lett. 242:237-239.
33. Oliviero, S., and R. Cortese. 1989. The human haptoglobin gene pro-
moter: interleukin-6-responsive elements interact with a DNA-binding protein
induced by interleukin-6. EMBO (Eur. MoI. Biol. Organ.) J. 8:1145-1151.
34. Kino, K., H. Tsunoo, Y. Higa, and H. Nakajima. 1982. Kinetic aspects of
hemoglobin-haptoglobin-receptor interaction in rat liver plasma membranes,
isolated liver cells, and liver cells in primary culture. J. Biol. Chem. 257:4828-
4833.
35. Kino, K., H. Tsunoo, Y. Higa, M. Takami, H. Hamaguchi, and H. Naka-
jima. 1980. Hemoglobin-haptoglobin receptor in rat liver plasma membrane. J.
Biol. Chem. 255:9618-9620.
36. Kushner, I. 1982. The phenomenon ofthe acute phase response. Ann. NY
Acad. Sci. 389:39-48.
37. Hansen, J. E. S., J. Iversen, A. Lihme, and T. C. Bog-Hansen. 1987. Acute
phase reaction, heterogeneity and microheterogeneity of serum proteins as non-
specific tumor markers in lung cancer. Cancer. 60:1630-1635.
38. Kuhajda, F. P., A. I. Katumuluwa, and G. R. Pasternak. 1989. Expression
of haptoglobin-related protein and its potential role as a tumor antigen. Proc.
Natl. Acad. Sci. USA. 86:1188-1192.
39. Agostoni, A., C. Vergani, R. Stabilini, B. Marasini, R. Arcidiacono, A.
Sbaffi, and P. C. Binaghi. 1970. Immunochemical quantitation of acute phase
proteins in myocardial infarction. Am. Heart J. 80:313-318.
40. Mueller, W. K., R. Handschumacher, and N. E. Wade. 1971. Serum
haptoglobin in patients with ovarian malignancies. Obstet. Gynecol. 38:427-435.
41. Snyder, S., and Ashwell, G. 1971. Quantitation of specific serum glyco-
proteins in malignancy. Clin. Chim. Acta. 34:449-455.
42. Oh, S. K., D. L. Very, J. Walker, S. Raam, and S. T. Ju. 1987. An analogy
between fetal haptoglobin and a potent immunosuppressant in cancer. Cancer
Res. 47:5120-5126.
43. Oh, S. K., S. H. Kim, and J. E. Walker. 1990. Interference with immune
response at the level ofgenerating effector cells by tumor-associated haptoglobin.
J. Natl. Cancer Inst. 82:934-940.
44. Folkman, J., K. Watson, D. Ingber, and D. Hanahan. 1989. Induction of
angiogenesis during the transition from hyperplasia to neoplasia. Nature (Lond.).
339:58-6 1.
45. Folkman, J. 1990. What is the evidence that tumors are angiogenesis
dependent? J. Natl. Cancer Inst. 82:4-6.
46. Eidner, N., J. P. Semple, W. R. Welch, and J. Folkman. 1991. Tumor
angiogenesis and metastasis. Correlation in invasive breast carcinoma. N. Engl. J.
Med. 324:1-8.
47. Chapelle, J. P., A. Albert, J. P. Smeets, C. Heusghem, and H. E. Kulbertus.
1982. Effect of the haptoglobin phenotype on the size ofa myocardial infarct. N.
Engl. J. Med. 307:457-463.
48. Panter, S. S., R. P. Bynigton, L. J. England, B. Schnasse, E. Rubin, M.
Petracek, S. R. Sundby, P. E. Hallaway, and B. E. Hedlund. 1991. Recovery from
myocardial infarction is related to haptoglobin genotype. Clin. Res. 39:347A.
49. Thompson, S., R. Stappenbeck, and G. A. Turner. 1989. A multiwell
lectin-binding assay using lotus tetranolobus for measuring different glycosylated
forms of haptoglobin. Clin. Chim. Acta. 180:227-284.
50. Shurbaji, M. S., T. S. Thurmond, G. R. Pasternack, and F. P. Kuhajda.
1991. Expression of haptoglobin related protein (Hpr) epitopes by prostate carci-
noma: a potential prognostic indicator. Lab. Invest. 64:52A.
51. Kuhajda, F. P., S. Piantadosi, and G. R. Pasternak. 1989. Haptoglobin-re-
lated protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the
disease. N. Engl. J. Med. 321:636-641.
Angiogenic Activity ofHaptoglobin 985
